Cohance Lifesciences Limited (BOM:543064)

Market Cap	165.08B -60.0%
Revenue (ttm)	22.69B -14.0%
Net Income	1.79B -63.2%
EPS	4.68 -63.1%
Shares Out	n/a
PE Ratio	92.10
Forward PE	60.44
Dividend	n/a
Ex-Dividend Date	n/a

Volume	52,746
Open	426.50
Previous Close	431.10
Day's Range	426.50 - 444.35
52-Week Range	267.85 - 1,121.15
Beta	n/a
Analysts	Hold
Price Target	516.78 (+20.35%)
Earnings Date	May 12, 2026

About Cohance Lifesciences

Cohance Lifesciences Limited engages in the contract research, development, and manufacturing of new chemical entity (NCE) based intermediates, active pharmaceutical ingredients (API), specialty chemicals, and formulated drugs in India, the United States, Europe, and internationally. The company offers small molecule APIs, advanced intermediates, and starting materials; antibody drug conjugates; high-purity oligonucleotide building blocks comprising phosphoramidites, nucleosides, pseudouridine, NTPs, CAP reagents, GalNAc conjugates, and fluores...

• Industry: Pharmaceutical Preparations
• Founded: 1989
• Employees: 1,212
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 543064

Financial Performance

In fiscal year 2026, Cohance Lifesciences's revenue was 23.03 billion, an increase of 92.27% compared to the previous year's 11.98 billion. Earnings were 1.79 billion, a decrease of -33.09%.